Replies to post #36593 on Humanigen Inc (HGENQ)

[DonDonDonDon]

At what market cap could HGEN be at if all went well by years' end? Is $2B a good number? $28.50 per share has a nice ring to it!

They potentially already have $1.25 billion in product to sell this year (125,000 treatments x $10,000). A $5 billion market cap should be easily attainable. That is a share price of $71.

[cowtown jay]

My single, open sell order, which expires on the 20th, is for a small portion of my shares in the $2B market cap level. I'd like to see the pre-market bid run past that and get a better fill.

I want to see how much appetite there is between the US and foreign governments for their national stockpile orders to treat hospitalized Covid patients. Sotrovimab had stockpile orders for hundreds of thousands of treatments, just for the US govt, and that mAb is proving ineffective for certain omicron variants, or for hypoxic patients. Altogether, they had purchase agreements for 1.7M treatments.

https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreement-to-purchase-additional-supply-of-sotrovimab/

I'd like to see Humanigen capture and extend that market, as only we are positioned to do.

The Wainwright analyst had a share price projection for VIR/GSK of over $200 per share because of these sotrovimab purchase agreements.